Deciphering cellular plasticity in pancreatic cancer for effective treatments

Cancer Metastasis Rev. 2024 Mar;43(1):393-408. doi: 10.1007/s10555-023-10164-5. Epub 2024 Jan 9.

Abstract

Cellular plasticity and therapy resistance are critical features of pancreatic cancer, a highly aggressive and fatal disease. The pancreas, a vital organ that produces digestive enzymes and hormones, is often affected by two main types of cancer: the pre-dominant ductal adenocarcinoma and the less common neuroendocrine tumors. These cancers are difficult to treat due to their complex biology characterized by cellular plasticity leading to therapy resistance. Cellular plasticity refers to the capability of cancer cells to change and adapt to different microenvironments within the body which includes acinar-ductal metaplasia, epithelial to mesenchymal/epigenetic/metabolic plasticity, as well as stemness. This plasticity allows heterogeneity of cancer cells, metastasis, and evasion of host's immune system and develops resistance to radiation, chemotherapy, and targeted therapy. To overcome this resistance, extensive research is ongoing exploring the intrinsic and extrinsic factors through cellular reprogramming, chemosensitization, targeting metabolic, key survival pathways, etc. In this review, we discussed the mechanisms of cellular plasticity involving cellular adaptation and tumor microenvironment and provided a comprehensive understanding of its role in therapy resistance and ways to overcome it.

Keywords: Cellular plasticity; Pancreatic cancer; Stemness; Therapy resistance.

Publication types

  • Review

MeSH terms

  • Carcinoma, Pancreatic Ductal* / pathology
  • Carcinoma, Pancreatic Ductal* / therapy
  • Cell Plasticity
  • Cellular Reprogramming
  • Humans
  • Pancreas
  • Pancreatic Neoplasms* / pathology
  • Pancreatic Neoplasms* / therapy
  • Tumor Microenvironment